MedWatch

Lundbeck Foundation wants stronger biotech businesses in Denmark, but this doesn't rule out international growth

A managing partner at Lundbeckfonden Emerge would like to see more biotech businesses growing bigger and staying in Denmark, but this doesn't mean they can't also go public in the US.

Photo: Lundbeckfonden / PR

When Danish biotech companies reach a certain size, the growth is usually supplemented by an acquisition offer from a bigger firm, often from abroad. There's nothing wrong with this model, says Christian Elling, managing partner at Lundbeckfonden Emerge, even if he would prefer to see a more of them stay in Denmark for longer, growing domestically.

This is not to say that firms must go public in Denmark with a Danish-centered approach, if this isn't in the best interest of investors, reports Danish media Finans.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs